Evidence map›Paper›PMID 41013216›Full record

ArticleBMC immunology2025

Establishment and validation of a recurrent prediction model for glioma: extrinsic apoptotic molecules FADD and CASP8 are closely associated with glioma recurrence.

Lanying Li, Lei Yang, Yanfang Zhang

Abstract readValidation Study
In one paragraph

Article in BMC immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Lanying Li *Department of Hematology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Lei Yang *Department of Hematology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Yanfang ZhangDepartment of Hematology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. 304224@hospital.cqmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlioma represents the most prevalent and aggressive primary brain tumor in humans. Tumor heterogeneity, the immunosuppressive tumor microenvironment, and therapeutic resistance contribute to the inevitable recurrence of gliomas, posing significant clinical challenges. Understanding the risk factors and molecular mechanisms underlying glioma recurrence and progression is critical for improving patient outcomes. In this study, we aimed to develop a recurrence-associated gene signature to predict clinical recurrence and survival outcomes while elucidating potential molecular mechanisms driving glioma recurrence.

methodsGene expression profiles and clinicopathological data were obtained from the Chinese Glioma Genome Atlas (CGGA) database. The CGGA-693 cohort served as the training set, while the CGGA-325 cohort and TCGA database were used for validation. A prognostic model was constructed using LASSO regression analysis. Cox regression and Kaplan-Meier survival analyses were employed to assess prognostic significance. Functional enrichment analyses, including Gene Ontology (GO), Gene Set Variation Analysis (GSVA), and Pearson correlation analysis, were conducted to explore biological pathways. We applied the T-test to analyze the expression levels of apoptotic molecules in primary versus recurrent gliomas, low-grade versus high-grade gliomas, as well as in the high versus low recurrence score groups. Furthermore, correlation analysis was performed to elucidate the relationship between six classic apoptotic genes and the recurrence score. By utilizing the STRING protein-interaction network, we systematically investigated the correlations between these six classic apoptotic genes and the 9-gene signature. RNA expression levels of CASP8 and FADD across various tissues were obtained from the NCBI database and the Human Protein Atlas database. Additionally, the protein levels of CASP8 and FADD in normal brain tissues were retrieved from the Human Protein Atlas database. Statistical analyses and visualization were performed using R software.

resultsA 9-gene recurrence-associated signature (AC062021.1, CCT7P2, CTB-1I21.1, DGCR6, RP11- 158M2.5, SLC22A6, SLC25A48, ADAM12, and FAM225B) was established, demonstrating robust predictive performance. Multivariate analysis confirmed that the recurrence score serves as an independent prognostic factor for glioma patients. Functional annotation revealed a significant association between the signature and apoptotic pathways. Subsequent analysis indicated that extrinsic apoptosis-related molecules (FADD and CASP8), rather than intrinsic apoptotic molecules (BCL2 and CASP9), were strongly correlated with glioma recurrence. Additionally, we characterized the expression patterns of key extrinsic apoptotic mediators, FADD and CASP8, in both normal and tumor tissues.

conclusionsOur study successfully developed a predictive model based on 9 recurrence-related genes, enabling accurate stratification of glioma patients into high- and low-risk recurrence groups. Furthermore, we identified apoptosis, particularly the extrinsic apoptotic pathway involving FADD and CASP8, as a critical mechanism associated with glioma recurrence. These findings provide valuable insights into the molecular basis of glioma recurrence and may facilitate the development of targeted therapeutic strategies.

Indexed as

Biomarkers, TumorBrain NeoplasmsCaspase 8Fas-Associated Death Domain ProteinGliomaNeoplasm Recurrence, LocalApoptosisFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisTranscriptomeBiomarkers, TumorCASP8 protein, humanCaspase 8FADD protein, humanFas-Associated Death Domain ProteinApoptosisCASP8FADDGliomaPrognostic modelRecurrence prediction

Identifiers

PMID41013216
PMCPMC12465967

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.